INSTANT-VIEW OPIATES/MORPHINE URINE DIP STRIP TEST

K994409 · Alfa Scientific Designs, Inc. · DPK · Jul 10, 2000 · Clinical Toxicology

Device Facts

• Record ID: K994409
• Device Name: INSTANT-VIEW OPIATES/MORPHINE URINE DIP STRIP TEST
• Applicant: Alfa Scientific Designs, Inc.
• Product Code: DPK · Clinical Toxicology
• Decision Date: Jul 10, 2000
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.3640
• Device Class: Class 2

Intended Use

The Instant-View™ Morphine Urine Dip Strip Test is a qualitative immunoassay device intended to detect morphine only in human urine at a cutoff level of 300 ng/ml. It is for health care professional use only.

Device Story

Instant-View Morphine Urine Dip Strip Test is a lateral flow, competitive binding immunoassay for qualitative detection of morphine in human urine. Device utilizes immunochemical sandwich assay principle; specific Morphine/Antibody/Morphine complexes form on test strip. Used by healthcare professionals in clinical settings or physician offices. Input is human urine sample; output is visual interpretation of test lines (C line only indicates positive at ≥300 ng/ml; C and T lines indicate negative). Preliminary results require confirmation via GC/MS or other specific chemical methods. Clinical judgment must be applied to results. Benefits include rapid, point-of-care screening for morphine presence.

Clinical Evidence

Bench testing and clinical evaluation performed. Accuracy evaluation conducted at a clinical laboratory and three physician offices by personnel with diverse backgrounds showed 96.2% agreement with expected results. Correlation with the predicate device was >91.3%. Agreement across three physician office laboratory (POL) sites was 92.5%.

Technological Characteristics

One-step lateral flow, competitive binding immunoassay. Utilizes immunochemical sandwich assay principle. Form factor is a dip strip. No external energy source required. Manual operation.

Indications for Use

Indicated for health care professionals to qualitatively detect morphine in human urine at a 300 ng/ml cutoff level. Provides preliminary analytical results; requires confirmation via alternate chemical methods like GC/MS.

Regulatory Classification

Identification

A morphine test system is a device intended to measure morphine, an addictive narcotic pain-relieving drug, and its analogs in serum, urine, and gastric contents. Measurements obtained by this device are used in the diagnosis and treatment of morphine use or overdose and in monitoring levels of morphine and its analogs to ensure appropriate therapy.

Special Controls

*Classification.* Class II (special controls). A morphine test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Predicate Devices

• QuikStrip One Step Opiate Test (K972571)

Submission Summary (Full Text)

{0}------------------------------------------------

K994409

## Alfa Scientific Designs, Inc.

11494 Sorrento Valley Road, Suite San Diego, CA 9212

# 510(K) Summary

In accordance with the Safe Medical Devices Act of 1990, a 510(K) summary is provided as outlined in 21 CFR 807.92.

| Submitter | Name: | Alfa Scientific Designs, Inc. |
|-----------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Address: | 11494 Sorrento Valley Road, Suite M<br>San Diego, CA 92121<br>Telephone: [phone]<br>Fax: [phone]<br>Email: [e-mail] |
| Device Name | Trade Name: | Instant-View™ Morphine Urine Dip Strip Test |
| | Common Name: | Opiate Test |
| | Classification Name: | 21 CFR 862.3650, Class II |
| Predicate Device | The Instant-View™ Morphine Urine Dip Strip Test is<br>substantially equivalent to other legally marketed devices<br>for the similar intended use. The device used for<br>comparison study is QuikStrip One Step Opiate Test,<br>manufactured by Syntron Bioresearch, Inc. with 510(K) #:<br>K972571, Date of Approval: 08/20/97. | |
| Device Description | This test is a one-step lateral flow chromatographic<br>immunoassay. | |
| Intended Use | The Instant-View™ Morphine Urine Dip Strip Test is a<br>qualitative immunoassay device intended to detect morphine<br>only in human urine at a cutoff level of 300 ng/ml. It is for<br>health care professional use only. | |
| Summary of the<br>Similarities to the<br>Predicate Device | | • Intended Use:<br>Both devices are intended to detect morphine in human<br>urine at a cutoff level of 300 ng/ml.<br>• Interpretation of results:<br>The appearance of only a C line indicates a positive<br>result, and that the morphine level is at a cutoff level of<br>300 ng/ml or higher. And, the appearance of two lines –<br>both C line and T line indicates a negative result, and the |

510(K) #: K994409 Summary: Instant-View™ Morphine Urine Dip Strip Test

{1}------------------------------------------------

| morphine level is below 300 ng/ml. |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • Technological Characteristics:<br>Both devices are one step, qualitative, competitive<br>binding immunoassay test, utilizing the basic<br>immunochemical sandwich assay principle of<br>recognition and formation of the specific Morphine/<br>Antibody/Morphine complexes. |
| <b>Discussion and Conclusion</b> |
| • The correlation of results from the Instant-View™ Morphine Urine Dip Strip Test, and the legally<br>marketed test device compared, is higher than 91.3 %.<br>The results from all three POL sites agreed 92.5%. |
| • The Accuracy evaluation results from the Clinical<br>Laboratory and three Physician's Offices conducted by<br>persons with diverse educational background and<br>working experience agreed 96.2 % with the expected<br>results. |
| • Based on the results of the Performance Characteristics<br>and Comparison Studies, it may be concluded that the<br>Instant-View™ Morphine Urine Dip Strip Test is<br>suitable for use by health care professionals with<br>diverse educational backgrounds and work experiences,<br>and is substantially equivalent to the existing legally<br>marketed device. |

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS). The seal features a stylized caduceus, a symbol often associated with medicine and healthcare, with three parallel lines forming the staff and a winding pattern representing snakes. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular pattern around the caduceus.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

### JUL 1 0 2000

Ms. Rhoda Filipina QA Manager Alfa Scientific Designs, Inc. 11494 Sorrento Valley Road Suite M San Diego, California 92121

K994409 Re:

> Trade Name: Instant-View Morphine Urine Dip Strip Test Regulatory Class: II Product Code: DPK Dated: June 6, 2000 Received: June 8, 2000

Dear Ms. Filipina:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

{3}------------------------------------------------

### Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally particed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at [phone]. Additionally, for questions on the promotion and advertising of your device a please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number [phone] or [phone] or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven Sutman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

K99440p

Page 1 of 1

K994409 510(k) Number (if known):

Instant-View Morphine Urine Dip Strip Test Device Name:

Indications For Use:

Instant-View Morphine Urine Dip Strip Test is a qualitative one step lateral flow, competitive binding immunoassay device intended to be used to detect morphine only in human urine at a cutoff level of 300 ng/ml. It is intended for health care professional use only.

The US Substance Abuse and Mental Health Services Administration (SAMHSA) recommends the screening levels for Morphine to be at a concentration of 2000 ng/ml.

This Test provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas Chromatography/Mass Spectrophotometry (GC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be applied to any drug of abuse, particularly when preliminary positive results are used. س

| (Division Sign-Off) | |
|-----------------------------------------|---------|
| Division of Clinical Laboratory Devices | |
| 510(k) Number | K994409 |

(Please Do NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109) OR

Over-The-Counter Use (Optional Format 1-2-96)